The past year has seen an unprecedented surge in regulatory, scientific, and media attention surrounding ashwagandha, a revered adaptogenic herb in Ayurvedic tradition. While some industry commentary has attempted to distill this intricate discussion into a seemingly straightforward narrative—positing that ashwagandha root represents the authentic, traditional form, while leaf signifies adulteration and potential safety concerns, with a blanket "total withanolides" percentage serving as a convenient quality benchmark—a closer examination of the scientific evidence reveals a far more nuanced reality. The core issue is not a lack of scientific understanding regarding ashwagandha’s efficacy or safety, but rather a pervasive problem of market consistency and accurate representation.
With nearly 200 clinical and safety studies already published on both root and leaf products, the scientific community possesses a wealth of knowledge about ashwagandha, exceeding that available for many other botanical ingredients. This extensive research base provides robust data on its safety, manufacturing processes, and chemical composition. The challenge, however, lies in the inconsistent application of these established scientific principles across the global marketplace, leading to confusion and potentially hindering the responsible growth of the ashwagandha sector.
A Regulatory Narrative Still Unfolding
Decisions impacting ashwagandha, like any natural product, reverberate through a complex ecosystem involving farmers, processors, manufacturers, exporters, brands, retailers, and ultimately, consumers. These decisions also influence regulatory bodies in other nations, creating a ripple effect on international trade and policy. Therefore, it is imperative that regulatory actions are grounded in a comprehensive understanding of the evidence, rather than being driven by overly simplified narratives.
A prime example of this complexity unfolded in India earlier this year. In April, the Food Safety and Standards Authority of India (FSSAI) issued an advisory stating that, under India’s food regulations, only ashwagandha roots and their extracts are permissible in food products. This was followed by a related directive from the Ministry of Ayush concerning the use of ashwagandha leaf within India. These pronouncements were particularly perplexing as they were issued without a thorough review of the scientific literature pertaining to ashwagandha leaf, which, as established, is supported by extensive clinical and safety evidence.
The media’s portrayal of these events often characterized the advisories as a global and permanent ban on ashwagandha leaf. However, the reality on the ground has proven to be far from settled. In India, several reputable firms challenged these directives, and the Karnataka High Court granted interim relief, effectively pausing the immediate enforcement of the advisory pending further legal proceedings. Current indications from reliable sources within India suggest that while the directives remain officially on record, their impact has been significantly mitigated by the High Court’s stay orders. Consequently, ashwagandha leaf continues to be available in the market. Reports also indicate internal divisions within the involved government agencies, with concerns raised about the reputational damage, impact on exports, and the repercussions for local farmers stemming from these actions.
Further analysis of market data from the Neemuch market, a significant trading hub for ashwagandha, does not support the intended outcome of restricting ashwagandha leaf. Post-advisory, leaf continued to be traded, although specific tracking data for leaf in the immediate months following the action was reportedly absent. Moreover, average root prices from September 2026 were observed to be lower than those recorded in September 2025, offering little evidence that the restriction on leaf strengthened demand for root. Concurrently, it appears that sub-standard suppliers and traders have largely maintained their operational and export capacities, suggesting that the measures did not effectively curb the activities of less scrupulous market participants.
The regulatory landscape in Europe is also in flux. The Netherlands, following a 2024 safety assessment by the Dutch National Institute for Public Health and the Environment (RIVM), had initially considered a broader prohibition on ashwagandha. However, the Dutch Ministry subsequently indicated that the proposed ban was likely to be rescinded as the RIVM undertakes a new assessment of ashwagandha root, based on additional scientific evidence. The differential treatment of ashwagandha leaf versus root persists for the time being. These evolving regulatory stances underscore the detrimental impact of arbitrary scrutiny, which can precipitate considerable confusion and hardship across the industry.
Leaf and Withaferin-A: Not Necessarily Adulteration
A legitimate quality and labeling concern arises when a product is marketed as ashwagandha root but contains undeclared leaf material. This is a clear breach of transparency and product integrity. However, it is crucial to differentiate this from the assertion that the presence of leaf itself constitutes adulteration. Withaferin A, a naturally occurring withanolide found in both the root and leaf of ashwagandha, has been unfairly targeted. This compound has been present, albeit in varying concentrations, in numerous characterized root, leaf, and root-and-leaf preparations that have been evaluated in extensive clinical and toxicological research.
While it is true that some unscrupulous suppliers may add leaf material to artificially inflate the "total withanolides" percentage, and that higher levels of Withaferin A can indeed signal the presence of leaf, the narrative suggesting this compound inherently possesses questionable safety is not substantiated by scientific evidence. Root-only, root-and-leaf, and other ashwagandha preparations are distinct materials. They must be accurately identified, appropriately characterized, and supported by scientific evidence relevant to the specific product being sold. The approach to safety assessment should mirror this precision.
Recent published safety studies on ashwagandha leaf further highlight the problematic nature of the prevailing narrative. A 2026 toxicological evaluation of an aqueous root-and-leaf extract (Sensoril) demonstrated excellent safety profiles, including a 90-day no-observed-adverse-effect-level (NOAEL) of 4,000 mg/kg/day in rats. Similarly, another recently published study on a standardized root-and-leaf extract (Shoden) reported no clinically significant changes in any measured safety parameters. Furthermore, a 2026 Phase 1 clinical trial involving patients with advanced non-small cell lung cancer found an ashwagandha leaf extract to be safe and well-tolerated. These findings are part of a growing body of evidence, building upon dozens of previously published studies on root and leaf preparations, that consistently support the safety of well-characterized ashwagandha leaf.
Established Methods for Testing Ashwagandha
A persistent misconception is that the industry is still awaiting scientific breakthroughs to resolve an "ashwagandha testing problem." This is inaccurate. The scientific and analytical communities have developed and validated methods for testing ashwagandha. The U.S. Pharmacopeia (USP) and AOAC International provide established methods for ashwagandha root and root extracts. Additionally, third-party laboratories offer validated methods for both root and leaf preparations, alongside robust method-performance requirements, reference standards, and method validation guidance. It is also anticipated that compendial methods for materials containing ashwagandha leaf will be developed in the near future.
The critical challenge, therefore, is not the absence of testing methodologies, but rather the consistent understanding and reproducible application of these methods across the market. This is particularly salient when products make label claims based on a "percent withanolides" metric. Key questions remain unanswered: Which specific withanolides are being measured? What analytical method and reference standards are being used? And how is the final percentage being calculated? Without clarity on these points, the "total withanolides" figure can become a misleading indicator of quality.
The Reality of Product Comparison
A December 2025 paper authored by Avula and colleagues at the University of Mississippi offers a compelling snapshot of the current market landscape. The researchers compared 25 commercial ashwagandha products using analytical approaches based on British Pharmacopoeia (BP) and USP standards. The findings revealed substantial variability: over 44% of the products failed to meet BP criteria, 60% failed USP criteria, and only 10 out of the 25 met both standards. It is important to note that none of the tested products were explicitly labeled as conforming to either USP or BP method requirements.
This disparity highlights several crucial points. Different ashwagandha extracts, by their very nature and extraction processes, can possess distinct chemical profiles. Analytical methods themselves have inherent limitations. The fundamental takeaway from this study is that if products exhibit significant chemical differences, these variations should be accurately characterized and understood, rather than being obscured by a single, often conflicting, numerical claim. This is precisely why advanced analytical techniques like High-Performance Liquid Chromatography (HPLC) and its derivatives are indispensable. They provide a chemical "fingerprint" that identifies the specific constituents within a botanical extract, offering a far more comprehensive picture than a simple percentage. Despite the substantial growth of the ashwagandha market, now estimated at $1.5 billion, a clear and consistent understanding of product composition remains elusive. Ultimately, analytical testing should serve the purpose of verifying quality and composition, not merely creating an illusion of it.
The Business Imperative for Stronger Standards
Beyond scientific accuracy and consumer protection, there is a significant business rationale for establishing and enforcing rigorous standards. Companies that are already investing heavily in quality control, research and development, and transparent labeling are the most vocal proponents of enhanced industry standards. When a diluted or poorly characterized product can make the same label claims as a meticulously manufactured one, responsible companies face multiple disadvantages. They bear the cost of producing a high-quality product, only to be undercut by unscrupulous competitors. Furthermore, consumers who do not receive the expected benefits from an inferior product may lose faith in the category altogether. Weak standards inadvertently subsidize poor practices and empower less ethical market players.
In recognition of these challenges, the Ashwagandha Standards Alliance (ASA) has emerged as a collaborative initiative aiming to unite stakeholders around critical issues facing the industry. The ASA comprises responsible ashwagandha producers, including prominent companies such as Sabinsa, Kerry, Arjuna Natural, and Cepham, alongside a growing contingent of reputable brands and analytical laboratories. This alliance underscores a shared commitment to elevating the standards and integrity of the ashwagandha market.
Ashwagandha: A Precursor to Broader Industry Evolution
The ongoing discourse surrounding ashwagandha is emblematic of a larger challenge facing the entire botanical extract industry. The very questions being raised about ashwagandha—its authenticity, standardization, and safety—are equally pertinent to numerous other widely used botanical ingredients, including turmeric, ginkgo, green tea, saffron, bilberry, and elderberry, among countless others.
As an individual deeply involved in the global botanical trade, this realization was particularly poignant during a recent visit to India, a nation where ashwagandha’s rich history, cultivation, and modern industrial landscape are intrinsically linked. My discussions there focused on our collective responsibility to honor both the people and the plants involved in this trade, and to ensure that the narrative surrounding these botanicals is accurate and evidence-based.
This necessitates a balanced approach: respecting traditional knowledge without allowing it to supplant empirical evidence, embracing modern scientific methodologies while avoiding the oversimplification of complex data, and acknowledging areas of uncertainty with intellectual honesty. Most crucially, it requires a profound understanding of each plant, an accurate description of its composition and properties, and a commitment to leaving the botanical extract category stronger and more trustworthy than we found it. If these principles are embraced, the implementation of stricter, science-based standards will not pose a threat to the ashwagandha market; rather, they will serve as its most potent protector and facilitator of sustainable growth.
